Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AURORA: MEDI0618 in Episodic Migraine
NCT06602479Phase 2Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Oct 2024
- Primary completion
- Feb 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of MEDI0618 in episodic migraine, sponsored by AbbVie Inc.. Started Oct 2024; status: active, not recruiting.
02
Drugs
MEDI0618
03
Conditions
episodic migraine
Beyond the preview
Go deeper on NCT06602479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06602479.